Business
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the
About this update from Tscan Therapeutics, Inc.
[{"type":"text","content":"WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD as well as virtually. Oral Presentation Details: Title: Discovery of Tumor Reactive TCRs and Their Cognate Antigenic Targets via High-Throughput Functional Screening Presenter: Candace Perullo Abstract Number: 419Session Title: Targeted Gene and Cell Therapy IISession Date/Time: Saturday, May 11; 10:15 a.m. - 12:00 p.m. Eastern TimePresentation Time: 11:15 - 11:30 a.m. Eastern TimeLocation: Room 318-323 Poster Presentation Details: Title: Nonclinical Development of T-Plex Component TSC-204-A0101: A Natural TCR-T Cell Therapy for the Treatment of MAGE-A1- and HLA-A*01:01-Positive Cancers Presenter: Shazad Khokhar, Ph.D.Abstract Number: 834Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell TherapiesSession Date/Time: Wednesday, May 8; 12:00 p.m. Eastern TimeLocation: Exhibit Hall Title: Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid TumorsPresenter: Hannah Bader, Ph.D.Abstract Number: 835Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell TherapiesSession Date/Time: Wednesday, May 8; 12:00 p.m. Eastern TimeLocation: Exhibit Hall Title: Trial in Progress: A Phase 1, First in Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid Tumors Presenter: Dawn Pinchasik, M.D.Abstract Number: 1900Session Title: Friday Posters: Cell Therapy and Cell-Based Gene Therapy TrialsSession Date/Time: Friday, May 10; 12:00 p.m. Eastern TimeLocation: Exhibit Hall Title: Trial in Progress: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation Pre...